HLS Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLTRF research report →
Companywww.hlstherapeutics.com
HLS Therapeutics Inc. , a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
- CEO
- Craig Stuart Millian
- IPO
- 2010
- Employees
- 92
- HQ
- Etobicoke, ON, CA
Price Chart
Valuation
- Market Cap
- $101.95M
- P/E
- -9.92
- P/S
- 1.83
- P/B
- 1.73
- EV/EBITDA
- 7.51
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 61.69%
- Op Margin
- -7.34%
- Net Margin
- -18.42%
- ROE
- -16.54%
- ROIC
- -3.66%
Growth & Income
- Revenue
- $56.47M · -0.26%
- Net Income
- $-12,647,593 · 35.65%
- EPS
- $-0.40 · 35.48%
- Op Income
- $-4,177,877
- FCF YoY
- 97.91%
Performance & Tape
- 52W High
- $4.02
- 52W Low
- $3.00
- 50D MA
- $3.27
- 200D MA
- $3.53
- Beta
- 0.90
- Avg Volume
- 167
Get TickerSpark's AI analysis on HLTRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HLTRF Coverage
We haven't published any research on HLTRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HLTRF Report →